Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Journal of Dentistry-Shiraz University of Medical Sciences. 2018; 19 (2): 150-154
Dans Anglais | IMEMR | ID: emr-198563

Résumé

Statement of the Problem: Macrophages are the target of attention in numerous diseases. Many studies reported them as the regulators of the growth, dissemination, and clinical behavior of various lesions. There are relatively scarce data regarding the role of macrophages in oral lesions, particularly odontogenic lesions


Purpose: This study investigated the macrophage density in odontogenic lesions of diverse biologic performance


Materials and Method: In this comparative analytical study, 60 cases of odontogenic lesions including ameloblastoma, keratocystic odontogenic tumor, dentigerous cyst, and radicular cyst were immunohistochemically stained with anti-CD68 antibody. One-way ANOVA and Tukey's HSD test were used for statistical analysis


Results: The results showed that the macrophage density in keratocystic odontogenic tumor [35.72+/-7.74] and ameloblastoma [46.12+/-9.84] was not significantly different from that in dentigerous cyst [43.87+/-8.13]. Interestingly, the macrophage density in keratocystic odontogenic tumor was lower than that in dentigerous cyst. No significant difference was observed in macrophage density between the ameloblastoma and much less aggressive lesions like dentigerous cyst [p= 0.59]. Macrophage density in radicular cyst [81.53+/-11.04] was significantly higher than other odontogenic lesions [p< 0.001]


Conclusion: The lack of significant differences in macrophage density between the known aggressive odontogenic tumors and much less aggressive lesions implied that macrophages might not contribute to the biological behavior of the odontogenic lesions. Therefore, it could support the notion that targeted therapy would not have prominent clinical potential to decrease the extent of mutilating surgeries in odontogenic lesions

2.
Journal of Dentistry-Shiraz University of Medical Sciences. 2018; 19 (3): 212-216
Dans Anglais | IMEMR | ID: emr-199512

Résumé

Statement of the Problem: Lichen planus disease is a chronic inflammatory lesion without a known etiology. Recent studies have indicated the role of vitamin D on immune system and proposed its anti-inflammatory effects


Purpose: This study aimed to compare vitamin D serum levels in patients with oral lichen planus and healthy subjects


Materials and Method: In this case.control study, 18 patients suffering from oral lichen planus referred to the Department of Oral Medicine, Tabriz Faculty of Den-tistry were chosen as the case group and 18 healthy people were chosen as the con-trol group. A 5-mL blood sample was taken from all subjects and the subjects' vitamin D serum levels were assessed with a vitamin D total [25-hydroxy vitamin D] kit by employing the electrochemiluminescence technique. The results were analyzed and compared by using SPSS17 statistic software. p< 0.05 was considered statistically significant


Results: The mean vitamin D level in serum of patients with oral lichen planus was 30.7+/- 20.38ng/ml and in healthy subjects was 36.45 +/- 15.33ng/ml, the difference was not statistically significant [p= 0.346]


Conclusion: The difference between the level of vitamin D in the serum of patients suffering from oral lichen planus and healthy individuals was not significant

3.
Journal of Dentistry-Shiraz University of Medical Sciences. 2017; 18 (3): 157-164
Dans Anglais | IMEMR | ID: emr-188513

Résumé

Temporomandibular joint disorders [TMDs] usually present with symptoms and signs such as pain, mandibular movement, dysfunction, or joint sounds. Botulinum toxin type A [BTX-A] is a biologic toxin which inhibits skeletal muscle through hindering the production of acetylcholine in the nerve endings. This toxin is used for the treatment of hyperactivity of lateral pterygoid muscle and TMD symptoms. This comprehensive review aimed to evaluate the effect of BTX-A injections in the lateral pterygoid muscle on treatment of TMDs symptoms.In this study, online databases including Scopus, Medline, Ebsco, Cochrane, EMBASE, and Google scholar were searched for the keywords [pterygoid muscle] and [Onabotulinumtoxin A]


Twenty-four articles were eligible to be enrolled in the study. In 4 interventional studies and 20 descriptive studies, BTX-A was used for the treatment of TMDs. The dosage and number of injections were different in each study; however, the injection methods were relatively similar. Regardless of the type, number of injections, and dosage, injection of BTX-A in lateral pterygoid seems effective in reducing the click sound and other TMJ-related muscle disorders such as pain, hyperactivity, and dysfunction


Sujets)
Toxines botuliniques/physiologie , Muscles ptérygoïdiens/effets des médicaments et des substances chimiques , Terminaisons nerveuses , Acétylcholine/physiologie , Bases de données comme sujet
SÉLECTION CITATIONS
Détails de la recherche